Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers:
4.1.1.1. Increasing Prevalence of Treprostinil Drugs Market and Technological Innovations in Treprostinil Drugs Market
4.1.2. Restraints:
4.1.2.1. Adverse effects associated with Some Spinocerebellar Ataxia (SCA)
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Forces Analysis
5.2. Regulatory Analysis
5.3. Supply Chain Analysis
5.4. Epidemiology
5.5. Unmet Needs
5.6. Product innovations
6. By Product Type
6.1. Introduction
6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment
6.1.2. Market Attractiveness Index, By Product Type Segment
6.2. Remodulin
6.2.1.1. Introduction
6.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
6.3. Tyvaso
6.4. Orenitram
7. By Distribution Channel
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
7.1.2. Market Attractiveness Index, By Distribution Channel Segment
7.2. Pharmacies
7.2.1.1. Introduction
7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Clinic Centers
7.4. Hospital pharmacies
7.5. Retail pharmacies
7.6. Online
8. By Region
8.1. Introduction
8.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
8.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
8.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
8.2.5.1. U.S.
8.2.5.2. Canada
8.2.5.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
8.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
8.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
8.3.5.1. Germany
8.3.5.2. U.K.
8.3.5.3. France
8.3.5.4. Italy
8.3.5.5. Spain
8.3.5.6. Rest of Europe
8.4. South America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
8.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
8.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
8.4.5.1. Brazil
8.4.5.2. Argentina
8.4.5.3. Rest of South America
8.5. Asia Pacific
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
8.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
8.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
8.5.5.1. China
8.5.5.2. India
8.5.5.3. Japan
8.5.5.4. Australia
8.5.5.5. Rest of Asia Pacific
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
8.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9. Competitive Landscape
9.1. Key Developments and Strategies
9.2. Company Share Analysis
9.3. Product Types Benchmarking
9.4. List of Key Companies to Watch
10. Company Profiles
10.1. United Therapeutics
10.1.1. Company Overview
10.1.2. Product Type Portfolio and Description
10.1.3. Key Highlights
10.1.4. Financial Overview
10.2. Novartis
10.3. Teva
10.4. Ascendis Pharma
10.5. Ferrer
10.6. Lee’s Pharmaceutical
10.7. Mochida Pharmaceutical
10.8. GlaxoSmithKline
10.9. Pfizer
LIST NOT EXHAUSTIVE
11. Global Treprostinil Drugs Market – DataM
11.1. Appendix
11.2. About Us and End User
11.3. Contact Us